CYP2D6 GENES AND RISK OF LIVER-CANCER

被引：60

作者：

AGUNDEZ, JAG

LEDESMA, MC

BENITEZ, J

LADERO, JM

RODRIGUEZLESCURE, A

DIAZRUBIO, E

DIAZRUBIO, M

机构：

[1] UNIV EXTREMADURA,SCH MED,DEPT PHARMACOL,E-06071 BADAJOZ,SPAIN

[2] UNIV COMPLUTENSE MADRID,SAN CARLOS UNIV HOSP,SERV ONCOL,MADRID,SPAIN

[3] UNIV COMPLUTENSE MADRID,SAN CARLOS UNIV HOSP,SERV GASTROENTEROL,MADRID,SPAIN

来源：

LANCET | 1995年 / 345卷 / 8953期

关键词：

D O I：

10.1016/S0140-6736(95)92965-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We have studied by use of PCR and Xbal and EcoRI restriction-fragment-length polymorphism whether mutations at the polymorphic CYP2D6 (debrisoquine hydroxylase) gene locus are associated with liver cancer. The frequency of CYP2D6 genes containing inactivating mutations was lower among 75 liver cancer patients than 200 healthy controls, and 40 cirrhotic subjects that did not develop liver cancer (frequency for carriers of two or more functional genes was 95% vs 74% vs 78%, respectively). Subjects who were homozygous for functional CYP2D6 genes appear to be at higher risk of developing primary liver cancer (odds ratio 6.40 [95% CI] 2.4-17.5).

引用

页码：830 / 831

页数：2

共 10 条

[1] DEBRISOQUIN OXIDATION GENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER
AGUNDEZ, JAG
MARTINEZ, C
LADERO, JM
LEDESMA, MC
RAMOS, JM
MARTIN, R
RODRIGUEZ, A
JARA, C
BENITEZ, J
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (01) : 10 - 14
[2] AGUNDEZ JAG, IN PRESS CLIN PHARM
[3] 5 OF 12 FORMS OF VACCINIA VIRUS-EXPRESSED HUMAN HEPATIC CYTOCHROME-P450 METABOLICALLY ACTIVATE AFLATOXIN-B1
AOYAMA, T
YAMANO, S
GUZELIAN, PS
GELBOIN, HV
GONZALEZ, FJ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (12) : 4790 - 4793
[4] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION
BROLY, F
GAEDIGK, A
HEIM, M
EICHELBAUM, M
MORIKE, K
MEYER, UA
[J]. DNA AND CELL BIOLOGY, 1991, 10 (08) : 545 - 558
[5] RELEVANCE OF METABOLIC POLYMORPHISMS TO HUMAN CARCINOGENESIS - EVALUATION OF EPIDEMIOLOGIC EVIDENCE
CAPORASO, N
LANDI, MT
VINEIS, P
[J]. PHARMACOGENETICS, 1991, 1 (01): : 4 - 19
[6] A TOBACCO SMOKE-DERIVED NITROSAMINE, 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE, IS ACTIVATED BY MULTIPLE HUMAN CYTOCHROME P450S INCLUDING THE POLYMORPHIC HUMAN CYTOCHROME P4502D6
CRESPI, CL
PENMAN, BW
GELBOIN, HV
GONZALEZ, FJ
[J]. CARCINOGENESIS, 1991, 12 (07) : 1197 - 1201
[7] GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION
HEIM, M
MEYER, UA
[J]. LANCET, 1990, 336 (8714) : 529 - 532
[8] INHERITED AMPLIFICATION OF AN ACTIVE GENE IN THE CYTOCHROME-P450 CYP2D LOCUS AS A CAUSE OF ULTRARAPID METABOLISM OF DEBRISOQUINE
JOHANSSON, I
LUNDQVIST, E
BERTILSSON, L
DAHL, ML
SJOQVIST, F
INGELMANSUNDBERG, M
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) : 11825 - 11829
[9] IDENTIFICATION OF A NEW VARIANT CYP2D6 ALLELE LACKING THE CODON ENCODING LYS-281 - POSSIBLE ASSOCIATION WITH THE POOR METABOLIZER PHENOTYPE
TYNDALE, R
AOYAMA, T
BROLY, F
MATSUNAGA, T
INABA, T
KALOW, W
GELBOIN, HV
MEYER, UA
GONZALEZ, FJ
[J]. PHARMACOGENETICS, 1991, 1 (01): : 26 - 32
[10] RELATIONSHIP BETWEEN THE DEBRISOQUINE HYDROXYLASE POLYMORPHISM AND CANCER SUSCEPTIBILITY
WOLF, CR
SMITH, CAD
GOUGH, AC
MOSS, JE
VALLIS, KA
HOWARD, G
CAREY, FJ
MILLS, K
MCNEE, W
CARMICHAEL, J
SPURR, NK
[J]. CARCINOGENESIS, 1992, 13 (06) : 1035 - 1038

← 1 →